» Articles » PMID: 36428611

Profiling the Adrenergic System in Breast Cancer and the Development of Metastasis

Abstract

Epidemiological studies and preclinical models suggest that chronic stress might accelerate breast cancer (BC) growth and the development of metastasis via sympathetic neural mechanisms. Nevertheless, the role of each adrenergic pathway (α1, α2, and β) in human samples remains poorly depicted. Herein, we propose to characterize the profile of the sympathetic system (e.g., release of catecholamines, expression of catecholamine metabolic enzymes and adrenoreceptors) in BC patients, and ascertain its relevance in the development of distant metastasis. Our results demonstrated that BC patients exhibited increased plasma levels of catecholamines when compared with healthy donors, and this increase was more evident in BC patients with distant metastasis. Our analysis using the BC-TCGA database revealed that the genes coding the most expressed adrenoreceptors in breast tissues (, and by order of expression) as well as the catecholamine synthesizing () and degrading enzyme ( and ) genes were downregulated in BC tissues. Importantly, the expression of , and was correlated with metastatic BC and BC subtypes, and thus the prognosis of the disease. Overall, we gathered evidence that under stressful conditions, both the α2- and β2-signaling pathways might work on a synergetic matter, thus paving the way for the development of new therapeutic approaches.

Citing Articles

The Use of Biologics for Targeting GPCRs in Metastatic Cancers.

McBrien C, OConnell D BioTech (Basel). 2025; 14(1).

PMID: 39982274 PMC: 11843943. DOI: 10.3390/biotech14010007.


Pan-cancer analysis of the role of α2C-adrenergic receptor (ADRA2C) in human tumors and validation in glioblastoma multiforme models.

Zhang X, Chen H, Wang C, Chen C, Liu L, Nie S J Cancer. 2024; 15(17):5691-5709.

PMID: 39308687 PMC: 11414618. DOI: 10.7150/jca.98240.


Effects of Selective and Nonselective Beta Blockers on Bone Mineral Density in Mexican Patients with Breast Cancer.

Mejia-Barradas C, Amador-Martinez A, Lara-Padilla E, Cardenas-Rodriguez N, Ignacio-Mejia I, Martinez-Lopez V Cancers (Basel). 2024; 16(16).

PMID: 39199661 PMC: 11352457. DOI: 10.3390/cancers16162891.


ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer.

Moreno P, Ohara Y, Craig A, Liu H, Yang S, Dorsey T Carcinogenesis. 2024; 45(11):845-856.

PMID: 39136088 PMC: 11584292. DOI: 10.1093/carcin/bgae056.


ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer.

Moreno P, Ohara Y, Craig A, Liu H, Yang S, Zhang L bioRxiv. 2024; .

PMID: 38903083 PMC: 11188071. DOI: 10.1101/2024.03.12.584316.


References
1.
Montoya A, Amaya C, Belmont A, Diab N, Trevino R, Villanueva G . Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Oncotarget. 2016; 8(4):6446-6460. PMC: 5351644. DOI: 10.18632/oncotarget.14119. View

2.
Lee A, Fraser S, Djamgoz M . Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: Effects of combination with ranolazine. J Cell Physiol. 2019; 234(12):23066-23081. DOI: 10.1002/jcp.28868. View

3.
Chang A, Le C, Walker A, Creed S, Pon C, Albold S . β2-Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer. Brain Behav Immun. 2016; 57:106-115. PMC: 5060133. DOI: 10.1016/j.bbi.2016.06.011. View

4.
Compas B, Stoll M, Thomsen A, Oppedisano G, Epping-Jordan J, Krag D . Adjustment to breast cancer: age-related differences in coping and emotional distress. Breast Cancer Res Treat. 1999; 54(3):195-203. DOI: 10.1023/a:1006164928474. View

5.
Dezong G, Zhongbing M, Qinye F, Zhigang Y . Carvedilol suppresses migration and invasion of malignant breast cells by inactivating Src involving cAMP/PKA and PKCδ signaling pathway. J Cancer Res Ther. 2015; 10(4):998-1003. DOI: 10.4103/0973-1482.137664. View